Navidea Biopharmaceuticals (NAVB) Stock Chart & Stock Price History $0.0005 0.00 (0.00%) As of 08/7/2025 10:25 AM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock Navidea Biopharmaceuticals Stock Price Performance The Navidea Biopharmaceuticals (NAVB) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 50.00%, with a year-to-date return of 400.00%. In the past month, the stock has increased 66.67%, reflecting recent market activity. As of the latest close, Navidea Biopharmaceuticals traded at $0.00 with a market cap of $50 thousand and volume of 1,768 shares. Five years ago, the stock traded at $4.77, representing a 99.99% decrease over that period. At the time, it had a market cap of $115.39 million and a volume of 5,748 shares. Receive NAVB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance0.00%1 Month Performance+66.67%3 Month Performance-16.67%Year-To-Date Performance+400.00%1 Year Performance-50.00%5 Year Performance-99.99% NAVB Stock Chart for Friday, August, 8, 2025 NAVB Chart by TradingView Navidea Biopharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/07/2025$0.00$0.00$0.00$0.001,768 shs$50,000.0008/06/2025$0.00$0.00$0.00$0.005,855 shs$50,000.0008/05/2025$0.00$0.00$0.00$0.001,000 shs$50,000.0008/04/2025$0.00$0.00$0.00$0.001,649 shs$50,000.0008/01/2025$0.00$0.00$0.00$0.002,480 shs$50,000.0007/31/2025$0.00$0.00$0.00$0.00223 shs$50,000.0007/30/2025$0.00$0.00$0.00$0.00192 shs$50,000.0007/29/2025$0.00$0.00$0.00$0.0080 shs$50,000.0007/25/2025$0.00$0.00$0.00$0.0050 shs$50,000.0007/24/2025$0.00$0.00$0.00$0.005,377 shs$50,000.00 Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/23/2025$0.00$0.00+400.00%$0.00$0.005,377 shs$50,000.0007/22/2025$0.00$0.00$0.00$0.002,266 shs$10,000.0007/21/2025N/A$0.00$0.00$0.0014,025 shs$10,000.0007/18/2025$0.00$0.00$0.00$0.00664 shs$10,000.0007/17/2025$0.00$0.00-50.00%$0.00$0.00664 shs$10,000.0007/16/2025$0.00$0.00$0.00$0.001,164 shs$20,000.0007/15/2025$0.00$0.00$0.00$0.00125 shs$20,000.0007/14/2025$0.00$0.00$0.00$0.00125 shs$20,000.0007/11/2025$0.00$0.00$0.00$0.0014,470 shs$20,000.0007/10/2025$0.00$0.00-33.33%$0.00$0.0014,470 shs$20,000.0007/09/2025$0.00$0.00$0.00$0.008,000 shs$30,000.0007/08/2025$0.00$0.00+50.00%$0.00$0.008,000 shs$30,000.0007/07/2025$0.00$0.00$0.00$0.00105 shs$20,000.00 Related Companies Universe Pharmaceuticals Stock Chart Virpax Pharmaceuticals Stock Chart Smart for Life Stock Chart Scopus BioPharma Stock Chart Evelo Biosciences Stock Chart Comera Life Sciences Stock Chart Genocea Biosciences Stock Chart Genocea Biosciences Stock Chart Aridis Pharmaceuticals Stock Chart Statera Biopharma Stock Chart Receive NAVB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:NAVB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
